Robert Orlowski, MD, PhD, professor of Medicine at The University of Texas MD Anderson Cancer Center, discusses prophylactic ...

Dr Alastair Hepburn and Dr Ho Juen Ko outline a rational approach to testing when investigating joint pains in a young adult ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

In this installment of The OncoloGIST, Hans Lee, MD, director of Myeloma Research at Sarah Cannon Research Institute, ...

Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and IMMUNOPLANT.

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...